| Record Information |
|---|
| Version | 5.0 |
|---|
| Status | Detected but not Quantified |
|---|
| Creation Date | 2021-09-11 03:57:02 UTC |
|---|
| Update Date | 2021-09-26 23:00:20 UTC |
|---|
| HMDB ID | HMDB0249439 |
|---|
| Secondary Accession Numbers | None |
|---|
| Metabolite Identification |
|---|
| Common Name | Bunazosin |
|---|
| Description | Bunazosin belongs to the class of organic compounds known as quinazolinamines. These are heterocyclic aromatic compounds containing a quianazoline moiety substituted by one or more amine groups. The mechanism of action is a reduction of aqueous outflow through the uveoscleral pathway resulting in lowering the intraocular pressure. Bunazosin is a very strong basic compound (based on its pKa). Bunazosin was initially developed to treat benign prostatic hyperplasia (BPH). Bunazosin potentially could have the same effect but there has been no research to substantiate this as a risk for cataract surgery. It also may act to improve blood flow to the ocular nerve. It has been approved in Japan in a topical form to treat glaucoma. Systemic Alpha-1 adrenergic receptor antagonists have been implicated in Intraoperative Floppy Iris Syndrome (IFIS). Bunazosin (INN) is an alpha 1 antagonist. This compound has been identified in human blood as reported by (PMID: 31557052 ). Bunazosin is not a naturally occurring metabolite and is only found in those individuals exposed to this compound or its derivatives. Technically Bunazosin is part of the human exposome. The exposome can be defined as the collection of all the exposures of an individual in a lifetime and how those exposures relate to health. An individual's exposure begins before birth and includes insults from environmental and occupational sources. |
|---|
| Structure | CCCC(=O)N1CCCN(CC1)C1=NC2=CC(OC)=C(OC)C=C2C(=N)N1 InChI=1S/C19H27N5O3/c1-4-6-17(25)23-7-5-8-24(10-9-23)19-21-14-12-16(27-3)15(26-2)11-13(14)18(20)22-19/h11-12H,4-10H2,1-3H3,(H2,20,21,22) |
|---|
| Synonyms | | Value | Source |
|---|
| BUNAZOSIN hydrochloride | ChEMBL, MeSH | | 4-amino-2-(4-butanoylhexahydro-1H-1,4-Diazepin-1-yl)-6,7-dimethoxyquinazoline HCL | MeSH | | Andante | MeSH | | Bunazocine | MeSH |
|
|---|
| Chemical Formula | C19H27N5O3 |
|---|
| Average Molecular Weight | 373.457 |
|---|
| Monoisotopic Molecular Weight | 373.211389749 |
|---|
| IUPAC Name | 1-[4-(4-imino-6,7-dimethoxy-3,4-dihydroquinazolin-2-yl)-1,4-diazepan-1-yl]butan-1-one |
|---|
| Traditional Name | andante |
|---|
| CAS Registry Number | Not Available |
|---|
| SMILES | CCCC(=O)N1CCCN(CC1)C1=NC2=CC(OC)=C(OC)C=C2C(=N)N1 |
|---|
| InChI Identifier | InChI=1S/C19H27N5O3/c1-4-6-17(25)23-7-5-8-24(10-9-23)19-21-14-12-16(27-3)15(26-2)11-13(14)18(20)22-19/h11-12H,4-10H2,1-3H3,(H2,20,21,22) |
|---|
| InChI Key | RHLJLALHBZGAFM-UHFFFAOYSA-N |
|---|
| Chemical Taxonomy |
|---|
| Description | Belongs to the class of organic compounds known as quinazolinamines. These are heterocyclic aromatic compounds containing a quianazoline moiety substituted by one or more amine groups. |
|---|
| Kingdom | Organic compounds |
|---|
| Super Class | Organoheterocyclic compounds |
|---|
| Class | Diazanaphthalenes |
|---|
| Sub Class | Benzodiazines |
|---|
| Direct Parent | Quinazolinamines |
|---|
| Alternative Parents | |
|---|
| Substituents | - Quinazolinamine
- Anisole
- Dialkylarylamine
- 1,4-diazepane
- Alkyl aryl ether
- Diazepane
- Aminopyrimidine
- Pyrimidine
- Benzenoid
- Imidolactam
- Tertiary carboxylic acid amide
- Heteroaromatic compound
- Carboxamide group
- Amino acid or derivatives
- Ether
- Carboxylic acid derivative
- Azacycle
- Organic nitrogen compound
- Organonitrogen compound
- Organooxygen compound
- Primary amine
- Carbonyl group
- Hydrocarbon derivative
- Organic oxide
- Organopnictogen compound
- Amine
- Organic oxygen compound
- Aromatic heteropolycyclic compound
|
|---|
| Molecular Framework | Aromatic heteropolycyclic compounds |
|---|
| External Descriptors | Not Available |
|---|
| Ontology |
|---|
| Not Available | Not Available |
|---|
| Physical Properties |
|---|
| State | Not Available |
|---|
| Experimental Molecular Properties | | Property | Value | Reference |
|---|
| Melting Point | Not Available | Not Available | | Boiling Point | Not Available | Not Available | | Water Solubility | Not Available | Not Available | | LogP | Not Available | Not Available |
|
|---|
| Experimental Chromatographic Properties | Not Available |
|---|
| Predicted Molecular Properties | |
|---|
| Predicted Chromatographic Properties | Predicted Collision Cross SectionsPredicted Retention Times Underivatized| Chromatographic Method | Retention Time | Reference |
|---|
| Predicted by Siyang on May 30, 2022 | 10.2403 minutes | 33406817 | | Predicted by Siyang using ReTip algorithm on June 8, 2022 | 2.17 minutes | 32390414 | | Fem_Long = Waters ACQUITY UPLC HSS T3 C18 with Water:MeOH and 0.1% Formic Acid | 1480.0 seconds | 40023050 | | Fem_Lipids = Ascentis Express C18 with (60:40 water:ACN):(90:10 IPA:ACN) and 10mM NH4COOH + 0.1% Formic Acid | 184.8 seconds | 40023050 | | Life_Old = Waters ACQUITY UPLC BEH C18 with Water:(20:80 acetone:ACN) and 0.1% Formic Acid | 153.1 seconds | 40023050 | | Life_New = RP Waters ACQUITY UPLC HSS T3 C18 with Water:(30:70 MeOH:ACN) and 0.1% Formic Acid | 162.8 seconds | 40023050 | | RIKEN = Waters ACQUITY UPLC BEH C18 with Water:ACN and 0.1% Formic Acid | 81.8 seconds | 40023050 | | Eawag_XBridgeC18 = XBridge C18 3.5u 2.1x50 mm with Water:MeOH and 0.1% Formic Acid | 324.4 seconds | 40023050 | | BfG_NTS_RP1 =Agilent Zorbax Eclipse Plus C18 (2.1 mm x 150 mm, 3.5 um) with Water:ACN and 0.1% Formic Acid | 378.0 seconds | 40023050 | | HILIC_BDD_2 = Merck SeQuant ZIC-HILIC with ACN(0.1% formic acid):water(16 mM ammonium formate) | 730.5 seconds | 40023050 | | UniToyama_Atlantis = RP Waters Atlantis T3 (2.1 x 150 mm, 5 um) with ACN:Water and 0.1% Formic Acid | 710.0 seconds | 40023050 | | BDD_C18 = Hypersil Gold 1.9µm C18 with Water:ACN and 0.1% Formic Acid | 236.1 seconds | 40023050 | | UFZ_Phenomenex = Kinetex Core-Shell C18 2.6 um, 3.0 x 100 mm, Phenomenex with Water:MeOH and 0.1% Formic Acid | 1359.3 seconds | 40023050 | | SNU_RIKEN_POS = Waters ACQUITY UPLC BEH C18 with Water:ACN and 0.1% Formic Acid | 214.3 seconds | 40023050 | | RPMMFDA = Waters ACQUITY UPLC BEH C18 with Water:ACN and 0.1% Formic Acid | 277.1 seconds | 40023050 | | MTBLS87 = Merck SeQuant ZIC-pHILIC column with ACN:Water and :ammonium carbonate | 357.7 seconds | 40023050 | | KI_GIAR_zic_HILIC_pH2_7 = Merck SeQuant ZIC-HILIC with ACN:Water and 0.1% FA | 409.4 seconds | 40023050 | | Meister zic-pHILIC pH9.3 = Merck SeQuant ZIC-pHILIC column with ACN:Water 5mM NH4Ac pH9.3 and 5mM ammonium acetate in water | 53.4 seconds | 40023050 |
Predicted Kovats Retention IndicesUnderivatizedDerivatized| Derivative Name / Structure | SMILES | Kovats RI Value | Column Type | Reference |
|---|
| Bunazosin,1TMS,isomer #1 | CCCC(=O)N1CCCN(C2=NC3=CC(OC)=C(OC)C=C3C(=N[Si](C)(C)C)[NH]2)CC1 | 3321.0 | Semi standard non polar | 33892256 | | Bunazosin,1TMS,isomer #1 | CCCC(=O)N1CCCN(C2=NC3=CC(OC)=C(OC)C=C3C(=N[Si](C)(C)C)[NH]2)CC1 | 3289.7 | Standard non polar | 33892256 | | Bunazosin,1TMS,isomer #1 | CCCC(=O)N1CCCN(C2=NC3=CC(OC)=C(OC)C=C3C(=N[Si](C)(C)C)[NH]2)CC1 | 5137.4 | Standard polar | 33892256 | | Bunazosin,1TMS,isomer #2 | CCCC(=O)N1CCCN(C2=NC3=CC(OC)=C(OC)C=C3C(=N)N2[Si](C)(C)C)CC1 | 3368.5 | Semi standard non polar | 33892256 | | Bunazosin,1TMS,isomer #2 | CCCC(=O)N1CCCN(C2=NC3=CC(OC)=C(OC)C=C3C(=N)N2[Si](C)(C)C)CC1 | 3239.5 | Standard non polar | 33892256 | | Bunazosin,1TMS,isomer #2 | CCCC(=O)N1CCCN(C2=NC3=CC(OC)=C(OC)C=C3C(=N)N2[Si](C)(C)C)CC1 | 5196.6 | Standard polar | 33892256 | | Bunazosin,2TMS,isomer #1 | CCCC(=O)N1CCCN(C2=NC3=CC(OC)=C(OC)C=C3C(=N[Si](C)(C)C)N2[Si](C)(C)C)CC1 | 3334.9 | Semi standard non polar | 33892256 | | Bunazosin,2TMS,isomer #1 | CCCC(=O)N1CCCN(C2=NC3=CC(OC)=C(OC)C=C3C(=N[Si](C)(C)C)N2[Si](C)(C)C)CC1 | 3294.9 | Standard non polar | 33892256 | | Bunazosin,2TMS,isomer #1 | CCCC(=O)N1CCCN(C2=NC3=CC(OC)=C(OC)C=C3C(=N[Si](C)(C)C)N2[Si](C)(C)C)CC1 | 4796.5 | Standard polar | 33892256 | | Bunazosin,1TBDMS,isomer #1 | CCCC(=O)N1CCCN(C2=NC3=CC(OC)=C(OC)C=C3C(=N[Si](C)(C)C(C)(C)C)[NH]2)CC1 | 3516.7 | Semi standard non polar | 33892256 | | Bunazosin,1TBDMS,isomer #1 | CCCC(=O)N1CCCN(C2=NC3=CC(OC)=C(OC)C=C3C(=N[Si](C)(C)C(C)(C)C)[NH]2)CC1 | 3530.8 | Standard non polar | 33892256 | | Bunazosin,1TBDMS,isomer #1 | CCCC(=O)N1CCCN(C2=NC3=CC(OC)=C(OC)C=C3C(=N[Si](C)(C)C(C)(C)C)[NH]2)CC1 | 5067.1 | Standard polar | 33892256 | | Bunazosin,1TBDMS,isomer #2 | CCCC(=O)N1CCCN(C2=NC3=CC(OC)=C(OC)C=C3C(=N)N2[Si](C)(C)C(C)(C)C)CC1 | 3552.4 | Semi standard non polar | 33892256 | | Bunazosin,1TBDMS,isomer #2 | CCCC(=O)N1CCCN(C2=NC3=CC(OC)=C(OC)C=C3C(=N)N2[Si](C)(C)C(C)(C)C)CC1 | 3465.9 | Standard non polar | 33892256 | | Bunazosin,1TBDMS,isomer #2 | CCCC(=O)N1CCCN(C2=NC3=CC(OC)=C(OC)C=C3C(=N)N2[Si](C)(C)C(C)(C)C)CC1 | 5059.0 | Standard polar | 33892256 | | Bunazosin,2TBDMS,isomer #1 | CCCC(=O)N1CCCN(C2=NC3=CC(OC)=C(OC)C=C3C(=N[Si](C)(C)C(C)(C)C)N2[Si](C)(C)C(C)(C)C)CC1 | 3670.2 | Semi standard non polar | 33892256 | | Bunazosin,2TBDMS,isomer #1 | CCCC(=O)N1CCCN(C2=NC3=CC(OC)=C(OC)C=C3C(=N[Si](C)(C)C(C)(C)C)N2[Si](C)(C)C(C)(C)C)CC1 | 3740.6 | Standard non polar | 33892256 | | Bunazosin,2TBDMS,isomer #1 | CCCC(=O)N1CCCN(C2=NC3=CC(OC)=C(OC)C=C3C(=N[Si](C)(C)C(C)(C)C)N2[Si](C)(C)C(C)(C)C)CC1 | 4678.7 | Standard polar | 33892256 |
|
|---|